Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’ Kisqali, and Eli Lilly’s Verzenio/Verzenios/Virginio) are creating new dynamics in the metastatic HR-positive/HER2-negative treatment practice. In HER2-positive breast cancer, emerging HER2-targeting drugs currently in development are forecasted to enter the market, while current HER2-targeting agents see their sales changing as a result of competition, label expansions, biosimilars entry and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Telzenna) and PD-1-targeting agents (Roche/Genentech/Chugai’s Tecentriq) and anticipated future entry of agents within these drug classes will provide more diverse treatment options, especially for triple-negative breast cancer.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.
Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.